{"organizations": [], "uuid": "cef901df224a4d8896467a49480e2f251acea835", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-synlogic-progresses-clinical-and-p/brief-synlogic-progresses-clinical-and-preclinical-pipeline-and-outlines-2018-catalysts-idUSFWN1P00DM", "country": "US", "domain_rank": 408, "title": "BRIEF-Synlogic Progresses Clinical And Preclinical Pipeline And Outlines 2018 Catalysts", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-05T15:19:00.000+02:00", "replies_count": 0, "uuid": "cef901df224a4d8896467a49480e2f251acea835"}, "author": "", "url": "https://www.reuters.com/article/brief-synlogic-progresses-clinical-and-p/brief-synlogic-progresses-clinical-and-preclinical-pipeline-and-outlines-2018-catalysts-idUSFWN1P00DM", "ord_in_thread": 0, "title": "BRIEF-Synlogic Progresses Clinical And Preclinical Pipeline And Outlines 2018 Catalysts", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "none"}, {"name": "synlogic inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 5, 2018 / 1:20 PM / Updated 4 minutes ago BRIEF-Synlogic Progresses Clinical And Preclinical Pipeline And Outlines 2018 Catalysts Reuters Staff \nJan 5 (Reuters) - Synlogic Inc: \n* SYNLOGIC PROGRESSES CLINICAL AND PRECLINICAL PIPELINE AND OUTLINES 2018 CATALYSTS \n* SYNLOGIC - EXPECTS TO PRESENT FULL CLINICAL DATA FROM FIRST IN-HUMAN STUDY OF SYNTHETIC BIOTIC MEDICINE EXPECTED IN Q1 2018 \n* SYNLOGIC INC - IND FOR SYNB1020 FOR TREATMENT OF HYPERAMMONEMIA IN PATIENTS WITH LIVER DISEASE HAS BEEN CLEARED BY FDA \n* SYNLOGIC INC - ADDITIONAL TRIALS IN PATIENTS WITH UCD AND PKU EXPECTED TO BEGIN IN 2018 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-05T15:19:00.000+02:00", "crawled": "2018-01-05T15:36:38.002+02:00", "highlightTitle": ""}